Table 3.

Associations between polymorphisms in UGT enzymes and breast cancer recurrence

 ER+/TAM+ER/TAM
 Cases/controlsConditional ORa(95% CI)Adjusted ORb(95% CI)Cases/controlsConditional ORa(95% CI)Adjusted ORb(95% CI)
UGT2B15*2
 2 normal alleles151/1401 (reference)1 (reference)85/871 (reference)1 (reference)
 1 variant allele237/2380.91 (0.68–1.2)1.0 (0.73–1.4)133/1301.1 (0.74–1.6)0.96 (0.60–1.5)
 2 variant alleles133/1390.83 (0.60–1.2)1.0 (0.70–1.5)71/691.1 (0.68–1.7)0.87 (0.50–1.5)
UGT2B7*2
 2 normal alleles127/1131 (reference)1 (reference)53/631 (reference)1 (reference)
 1 variant allele224/2320.88 (0.65–1.2)0.84 (0.58–1.2)142/1421.3 (0.82–2.0)0.97 (0.57–1.7)
 2 variant alleles163/1620.91 (0.65–1.3)0.96 (0.65–1.4)87/771.4 (0.85–2.2)1.0 (0.57–1.8)
UGT1A8*3
 2 normal alleles502/4941 (reference)1 (reference)284/2831 (reference)1 (reference)
 >1 variant allelec20/240.75 (0.41–1.4)0.95 (0.49–1.9)8/90.89 (0.34–2.3)0.95 (0.31–2.9)
Concordant ER+/TAM+(94% of original ER+/TAM+ cases and controls)Concordant ER/TAM(74% of original ER/TAMcases and controls)
CYP2D6*4, no variant alleles
UGT2B15*2
 2 normal alleles81/751 (reference)36/281 (reference)
 1 variant allele121/1351.0 (0.63–1.7)57/550.97 (0.45–2.1)
 2 variant alleles61/741.0 (0.59–1.8)27/350.50 (0.21–1.2)
UGT2B7*2
 2 normal alleles71/611 (reference)31/341 (reference)
 1 variant allele125/1370.83 (0.51–1.4)54/521.1 (0.50–2.3)
 2 variant alleles64/810.81 (0.46–1.4)32/320.84 (0.38–1.9)
UGT1A8*3
 2 normal alleles249/2691 (reference)117/1161 (reference)
 ≥1 variant allelec11/111.1 (0.42–2.6)2/30.62 (0.08–4.7)
CYP2D6*4, 1 or 2 variant alleles
UGT2B15*2
 2 normal alleles54/451 (reference)22/221 (reference)
 1 variant allele86/840.93 (0.52–1.7)35/430.72 (0.28–1.9)
 2 variant alleles29/360.72 (0.34–1.5)17/101.2 (0.34–3.9)
UGT2B7*2
 2 normal alleles42/401 (reference)14/151. (reference)
 1 variant allele72/730.85 (0.44–1.6)33/400.91 (0.30–2.8)
 2 variant alleles53/510.99 (0.49–2.0)24/171.5 (0.41–5.1)
UGT1A8*3
 2 normal alleles164/1561 (reference)71/721 (reference)
 >1 variant allelec7/100.94 (0.29–3.1)3/41.1 (0.19–6.0)
  • aEstimated with logistic regression models conditioned on matching variables (time to recurrence, county of residence, menopausal status at diagnosis, and tumor stage).

  • bEstimated with logistic regression models adjusted for tumor stage (categorical, design variables), menopausal status at diagnosis (pre or post), receipt of adjuvant systemic chemotherapy (dichotomous), receipt of adjuvant radiotherapy (dichotomous), type of surgery (mastectomy or breast-conserving), time to recurrence (for risk-set sampling of controls, continuous), and histologic grade (categorical, design variables).

  • cThere were no UGT1A8*3 homozygous variant cases or controls in the ER/TAM stratum, so analyses were carried out with heterozygotes combined with variant homozygotes.